BNTX logo

BioNTech SE (BNTX)

Profile

Full Name

BioNTech SE

Ticker Symbol

BNTX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

Germany

IPO

October 10, 2019

Indexes

Not included

Website

http://www.biontech.de

Employees

6772

Key Details

Price

$101.10(-3.66%)

Market cap

Last Dividend

$2.13

TTM Dividend yield

-

Annual revenue

$2.98B(-27.98% YoY)

Annual EPS

-$3.00(-172.31% YoY)

PE ratio

-

Next earnings date

N/A

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$101.10
BNTX price is $101.10

30-Day Relative Volume

0.58
BNTX 30-day relative volume is 0.58

Price Performance

Price Today change

-3.66%
BNTX price is down -3.66% today

Price YTD change

-11.28%
BNTX price is down -11.28% since January 1st

Price 1-year change

+9.04%
BNTX price is up +9.04% year-on-year

Price 3-year change

-28.76%
BNTX price is down -28.76% over the past 3 years

Price Range

Price All-time high

$464.00
BNTX price is currently -78.21% below its historical high of $464.00

Price 3-year low

$76.53
BNTX price is currently +32.11% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$24.30B
BNTX market capitalization is $24.30 billion

Market cap 3-year change

-30.03%
BNTX market capitalization is down -30.03% over the past 3 years

Market cap All-time high

$108.46B
BNTX market capitalization is currently -77.59% below its historical high of $108.46 billion

Market cap sector rank

96.09%
BNTX market capitalization is higher than 96.09% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

-0.25%
BNTX shares outstanding is down -0.25% year-on-year

Shares Outstanding 3-Year Change

-1.79%
BNTX shares outstanding is down -1.79% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.87
BNTX beta is 0.87

200-day SMA

$106.51
BNTX price is currently -5.08% below its 200-day simple moving average

50-day SMA

$101.39
BNTX price is currently -0.29% below its 50-day simple moving average

RSI

49.02
BNTX 14-day relative strength index is 49.02

Volume

0.58
BNTX 30-day relative volume is 0.58

ATR

$8.11
BNTX average true range is $8.11

10-day Historical Volatility

104.28%
BNTX 10-day historical volatility is 104.28%

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Last Paid Dividend

$2.13
BNTX last dividend was $2.13 per share, with an ex-dividend date of June 2, 2022

Next Dividend

-
BNTX next dividend has not yet been announced

Dividend per share

Dividend per share

-
BNTX annual dividend per share value is unknown

Dividend per share Sector Rank

-
BNTX annual dividend per share is unknown

Dividend per share 1-Year Change

-
BNTX annual dividend per share 1-year change is unknown

Dividend per share 3-Year Change

-
BNTX annual dividend per share 3-year change is unknown

Dividend yield

Dividend yield

-
BNTX annual dividend yield value is unknown

Dividend yield Sector Rank

-
BNTX annual dividend yield is unknown

Other

Payout ratio

0.00%
BNTX annual payout ratio is 0.00%

Dividends paid

$0.00
BNTX annual dividends paid is $0.00

Free cash flow

-$264.74M
BNTX annual free cash flow is -$264.74 million

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$2.98B
BNTX annual revenue is $2.98 billion

Revenue Analysts estimate

$2.11B
BNTX annual revenue is currently +40.82% higher than the consensus analysts' forecast

Revenue 1-year change

-27.98%
BNTX annual revenue is down -27.98% year-on-year

Revenue Sector rank

88.41%
BNTX annual revenue is higher than 88.41% of companies in Healthcare sector

EPS

EPS

-$3.00
BNTX annual earnings per share is -$3.00

EPS Analysts estimate

-$5.11
BNTX annual earnings per share is currently -41.37% lower than the consensus analysts' forecast

EPS 1-year change

-172.31%
BNTX annual earnings per share is down -172.31% year-on-year

EPS Sector rank

29.24%
BNTX annual earnings per share is higher than 29.24% of companies in Healthcare sector

Profit

Gross profit

$2.39B
BNTX annual gross profit is $2.39 billion

Gross margin

80.32%
BNTX annual gross profit margin is 80.32%

Operating profit

-$644.76M
BNTX annual operating income is -$644.76 million

Operating margin

-21.65%
BNTX annual operating profit margin is -21.65%

Net income

-$720.09M
BNTX annual net profit is -$720.09 million

Net margin

-24.18%
BNTX annual net profit margin is -24.18%

Expenses

Total expenses

$3.62B
BNTX annual total expenses is $3.62 billion

Operating expenses

$3.04B
BNTX annual total operating expenses is $3.04 billion

Cost of goods sold

$585.88M
BNTX annual cost of goods sold is $585.88 million

Selling, general & administrative expenses

$648.33M
BNTX annual SGA is $648.33 million

Depreciation and amortization

$322.54M
BNTX annual depreciation & amortization is $322.54 million

Interest expense

$13.64M
BNTX annual interest expense is $13.64 million

Income tax

-$13.42M
BNTX annual income tax is -$13.42 million

EBIT & EBITDA

EBIT

-$719.87M
BNTX annual earnings before interest & taxes is -$719.87 million

EBITDA

-$397.33M
BNTX annual EBITDA is -$397.33 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$23.44B
BNTX annual total assets is $23.44 billion

Non current assets

$3.88B
BNTX annual long term assets is $3.88 billion

Current assets

$19.57B
BNTX annual total current assets is $19.57 billion

Cash and cash equivalents

$10.16B
BNTX annual cash & cash equivalents is $10.16 billion

Accounts receivable

$1.52B
BNTX annual accounts receivable is $1.52 billion

Inventory

$294.79M
BNTX annual inventory is $294.79 million

Liabilities

Total liabilities

$3.25B
BNTX annual total liabilities is $3.25 billion

Long term liabilities

$619.56M
BNTX annual total long term liabilities is $619.56 million

Current liabilities

$2.63B
BNTX annual total current liabilities is $2.63 billion

Accounts payable

$444.01M
BNTX annual accounts payable is $444.01 million

Debt

Total debt

$264.51M
BNTX annual total debt is $264.51 million

Total debt 1-year change

+9.22%
BNTX annual total debt is up +9.22% year-on-year

Long term debt

$223.41M
BNTX annual long term debt is $223.41 million

Short term debt

$41.10M
BNTX annual short term debt is $41.10 million

Equity & Capital

Shareholders equity

$20.20B
BNTX annual stockholders equity is $20.20 billion

Book value

$20.20B
BNTX annual book value is $20.20 billion

Retained earnings

$19.87B
BNTX annual retained earnings is $19.87 billion

Working capital

$16.94B
BNTX annual working capital is $16.94 billion

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$224.80M
BNTX annual cash flow from operations is $224.80 million

Cash from operations 1-year change

-96.13%
BNTX annual cash flow from operations is down -96.13% year-on-year

Cash from investing

-$2.25B
BNTX annual cash flow from investing activities is -$2.25 billion

Cash from investing 1-year change

+70.08%
BNTX annual cash flow from investing activities is up +70.08% year-on-year

Cash from financing

-$49.68M
BNTX annual cash flow from financing activities is -$49.68 million

Cash from financing 1-year change

+94.11%
BNTX annual cash flow from financing activities is up +94.11% year-on-year

CAPEX

CAPEX

$489.55M
BNTX annual capital expenditures is $489.55 million

CAPEX 1-year change

-35.9%
BNTX annual capital expenditures is down -35.9% year-on-year

Free Cash Flow

Free cash flow

-$264.74M
BNTX annual free cash flow is -$264.74 million

Free cash flow 1-year change

-105.24%
BNTX annual free cash flow is down -105.24% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

80.32%
BNTX annual gross profit margin is 80.32%

Operating margin

-21.65%
BNTX annual operating profit margin is -21.65%

Net margin

-24.18%
BNTX annual net profit margin is -24.18%

ROA & ROE

ROA

-2.95%
BNTX annual return on assets is -2.95%

ROE

-3.38%
BNTX annual return on equity is -3.38%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
BNTX price to earnings ratio value is unknown

PE ratio Sector rank

-
BNTX price to earnings ratio is unknown

PB Ratio

PB ratio

1.20
BNTX price to book ratio is 1.20

PB ratio Sector rank

46.12%
BNTX price to book ratio is higher than 46.12% of companies in Healthcare sector

PS Ratio

PS ratio

8.16
BNTX price to sales ratio is 8.16

PS ratio Sector rank

73.96%
BNTX price to sales ratio is higher than 73.96% of companies in Healthcare sector

Enterprise value

Enterprise value

$14.41B
BNTX enterprise value is $14.41 billion

Enterprise value Sector rank

94.33%
BNTX enterprise value is higher than 94.33% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-36.71
BNTX EV/EBITDA is -36.71

EV/EBITDA Sector rank

4.71%
BNTX EV/EBITDA is higher than 4.71% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

7.45
BNTX annual current ratio is 7.45

Quick ratio

7.34
BNTX annual quick ratio is 7.34

Leverage

Debt to equity

0.01
BNTX annual debt to equity ratio is 0.01

Interest coverage ratio

-52.79
BNTX annual interest coverage ratio is -52.79

Risk & Stability

Piotroski F-Score

2
BNTX piotroski f-score is 2

Altman Z-Score

6.57
BNTX altman z-score is 6.57

Analyst ratings

Recent major analysts updates

Apr 1, 25 HC Wainwright & Co.
Buy
Mar 13, 25 Citigroup
Buy
Mar 11, 25 Morgan Stanley
Overweight
Mar 11, 25 Canaccord Genuity
Buy
Mar 11, 25 BMO Capital
Outperform
Jan 10, 25 Truist Securities
Buy
Dec 11, 24 Wells Fargo
Overweight
Nov 27, 24 Canaccord Genuity
Buy
Nov 26, 24 JP Morgan
Neutral
Nov 19, 24 Evercore ISI Group
Outperform

Institutional Ownership

Similar stocks

PHG logo
Koninklijke Philips NV (PHG)
MTD logo
Mettler-Toledo International (MTD)
STE logo
STERIS (STE)
IQV logo
IQVIA Holdings (IQV)
NTRA logo
Natera (NTRA)
BeiGene (ONC)
SMMT logo
Summit Therapeutics (SMMT)
WAT logo
Waters (WAT)
LH logo
Laboratory Corporation of America Holdings (LH)
  • What is the ticker symbol for BioNTech SE?
  • Does BioNTech SE pay dividends?
  • What sector is BioNTech SE in?
  • What industry is BioNTech SE in?
  • What country is BioNTech SE based in?
  • When did BioNTech SE go public?
  • Is BioNTech SE in the S&P 500?
  • Is BioNTech SE in the NASDAQ 100?
  • Is BioNTech SE in the Dow Jones?
  • When was BioNTech SE's last earnings report?
  • When does BioNTech SE report earnings?

What is the ticker symbol for BioNTech SE?

The ticker symbol for BioNTech SE is NASDAQ:BNTX

Does BioNTech SE pay dividends?

No, BioNTech SE does not pay dividends

What sector is BioNTech SE in?

BioNTech SE is in the Healthcare sector

What industry is BioNTech SE in?

BioNTech SE is in the Biotechnology industry

What country is BioNTech SE based in?

BioNTech SE is headquartered in Germany

When did BioNTech SE go public?

BioNTech SE's initial public offering (IPO) was on October 10, 2019

Is BioNTech SE in the S&P 500?

No, BioNTech SE is not included in the S&P 500 index

Is BioNTech SE in the NASDAQ 100?

No, BioNTech SE is not included in the NASDAQ 100 index

Is BioNTech SE in the Dow Jones?

No, BioNTech SE is not included in the Dow Jones index

When was BioNTech SE's last earnings report?

BioNTech SE's most recent earnings report was on May 5, 2025

When does BioNTech SE report earnings?

The date for BioNTech SE's next earnings report has not been announced yet
On this page